SARS CoV-2 IgM S1
HEK293 Cells
Description
Recombinant Anti Human SARS CoV-2 IgM Kappa Spike S1 is a recombinant monoclonal antibody derived from HEK293 cells which recognizes the SARS-CoV and SARS-CoV-2 Spike glycoprotein. CoV-2 IgM S1 Antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity at amino acids 318-510 (RBD, Receptor Binding Domain) in the S1 subunit of the Spike protein.
Product Specs
This product is suitable for use in ELISA applications.
For short-term storage, the product should be kept at 4°C, where it remains stable for up to 2 weeks. For extended storage, the product should be stored at -20°C.
HEK293 Cells
Affinity purified via recombinant lectin column.
The native monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
Mouse Anti Human SARS CoV-2 IgM Kappa Spike S1 Reformatted using the variable domain sequences of the original Human IgG1 format.
Product Science Overview
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to an unprecedented global health crisis. In response, the scientific community has developed various tools to study and combat the virus. One such tool is the recombinant anti-human SARS-CoV-2 IgM Spike S1 antibody. This article delves into the background, structure, and significance of this antibody.
The SARS-CoV-2 virus is characterized by its spike (S) glycoprotein, which plays a crucial role in the virus’s ability to infect host cells. The spike protein is divided into two subunits: S1 and S2. The S1 subunit contains the receptor-binding domain (RBD), which is responsible for binding to the host cell receptor, angiotensin-converting enzyme 2 (ACE2). This binding is the first step in the viral entry process.
The recombinant anti-human SARS-CoV-2 IgM Spike S1 antibody specifically targets the S1 subunit of the spike protein. This antibody is engineered to recognize and bind to the S1 subunit, thereby inhibiting the virus’s ability to attach to and enter host cells. The IgM isotype of this antibody is particularly significant because IgM antibodies are the first to be produced in response to an infection and can form pentamers, increasing their binding strength and effectiveness.
Recombinant antibodies are produced using genetic engineering techniques. The genes encoding the antibody’s variable regions are cloned into expression vectors, which are then introduced into host cells, such as Chinese hamster ovary (CHO) cells. These host cells produce the antibody, which is then purified and characterized.
The development of the recombinant anti-human SARS-CoV-2 IgM Spike S1 antibody involves several steps:
- Identification of the Target Epitope: Researchers identify the specific region of the S1 subunit that the antibody will target.
- Cloning and Expression: The genes encoding the antibody are cloned into expression vectors and introduced into host cells.
- Purification: The antibody is purified from the host cell culture using techniques such as affinity chromatography.
- Characterization: The antibody is characterized to ensure its specificity and binding affinity to the S1 subunit.
The recombinant anti-human SARS-CoV-2 IgM Spike S1 antibody has several important applications:
- Diagnostic Tools: This antibody can be used in diagnostic assays, such as enzyme-linked immunosorbent assays (ELISAs), to detect the presence of the SARS-CoV-2 virus in patient samples.
- Therapeutic Potential: Although primarily used for research and diagnostic purposes, there is potential for therapeutic applications. By neutralizing the virus, this antibody could be used as a treatment for COVID-19.
- Research: The antibody is a valuable tool for researchers studying the structure and function of the SARS-CoV-2 spike protein, as well as the immune response to the virus.
